To our knowledge, this is the first study to present the role and mechanism of VDR in NSCLC EGFR-TKI resistance, offering a novel approach to enhance the potential value of 1,25(OH)2D3 in NSCLC through targeting VDR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.